Teligent

Teligent develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada.  They are a dynamic group of about 130 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Their Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. In 2015 They acquired Alveda Pharmaceuticals Inc., a Toronto-based pharmaceutical company focused on the Canadian injectable pharmaceutical market. In 2016 They hired Their first European colleagues in Tallinn who support Their supply chain and quality operations.

VJGJ, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over the counter, and cosmetic markets. The company was founded by Jane E. Hager on August 26, 1977 and is headquartered in Buena, NJ.

Teligent (TLGT) delivered earnings and revenue surprises of -50.00% and -20.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Teligent (TLGT) Reports Q1 Loss, Misses Revenue Estimates

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q1 2019 Results - Earnings Call Transcript

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q4 2018 Results - Earnings Call Transcript

News for Teligent Stock (TLGT)